One‐Step Nucleic Acid Amplification Analysis of Sentinel Lymphatic Nodes in Endometrial Cancer Patients ( EU ‐ OSNA ): A European Multicenter Diagnostic Accuracy Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71268 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jan Kostun und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Nucleic Acid Amplification Techniques, Sentinel Lymph Node, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sysmex Corporation, MATC Science Area, National Institute for Cancer Research-NICR.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This European multicenter study aimed to assess the diagnostic accuracy of one‐step nucleic acid amplification (OSNA) as the primary endpoint by comparing this method with ultrastaging for the detection of sentinel node metastases in endometrial cancer patients.
Methods
European multicenter prospective performance study including data from 10 centers across 5 European countries. Each node, upon removal of surrounding adipose tissue, was sliced in 2 mm thick sections and equally distributed between ultrastaging and OSNA. OSNA is based on cytokeratin‐19 detection, serving as a metastatic marker. Sensitivity, specificity, and concordance of OSNA versus ultrastaging were calculated at nodal and patient levels.
Results
Seven hundred forty‐three sentinel nodes from 366 patients were evaluated. Compared to ultrastaging, OSNA showed concordance, specificity, and sensitivity of 95%, 97.6%, and 41.2% at the nodal level and 93.2%, 96.2%, and 47.8% at the patient level, respectively. In reverse analysis, when compared to OSNA, the ultrastaging showed a sensitivity of 45.2% and 45.8% at the nodal and patient levels, respectively. Irrespective of the size of metastasis, both methods agreed in 14 positive and 692 negative nodes (95%). This resulted in 24 (6.56%) patients with a positive OSNA and 23 (6.28%) patients with a positive ultrastaging finding. The number of discordant nodes was 47 (6.33%), 40 (85.1%) of them were micrometastases. Benign epithelial inclusions occurred in 4 nodes (0.54%) and 4 patients (1.09%).
Conclusion
Compared with ultrastaging, OSNA showed high concordance and specificity, but sensitivity was low—similar to ultrastaging compared with OSNA as an index test in reverse analysis. The main limitation in comparing the two approaches by splitting the sentinel nodes was the tissue allocation bias. As reflected in the number of discordant cases, especially at the micrometastases level. The distribution of patients with node metastases was comparable between the two methods at both the nodal and patient levels. Trial Registration German Clinical Trial Register: Nr. DRKS00021520
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
- Department of Gynecology and Gynecological Oncology, University Clinical Center of Medical University of Silesia, Katowice, Poland.
- Department of Gynecology and Gynecological Oncology, District Teaching Hospital, Czeladz, Poland.
- Department of Oncological Gynecology, Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland.
- Department of Gynecological Oncology, Wroclaw Medical University, Wroclaw, Poland.
- Department of Pathology, Hospital Universitario La Paz, Madrid, Spain.
ORCID-Profile: Jan Kostun, David Hardisson, Martin Pešta, Giuseppe Vizzielli
Förderung
- Sysmex Corporation
- MATC Science Area
- National Institute for Cancer Research-NICR
- European Union-Next Generation EU
Zitieren
APA
Kostun, J., Nowosielski, K., Jedryka, M. A., Hardisson, D., Restaino, S., Gatius, S., Novak, Z., Lacalle, A. S., Lopez, S., Pešta, M., Zebalski, M., Lepka, P., Diestro, M. D., Vizzielli, G., Matias-Guiu, X., Echim, T., Urkaray, E. N. C., Rienda, I., Slunečko, R., …, & Presl, J. (2025). One‐Step Nucleic Acid Amplification Analysis of Sentinel Lymphatic Nodes in Endometrial Cancer Patients ( EU ‐ OSNA ): A European Multicenter Diagnostic Accuracy Study. Cancer Medicine. https://doi.org/10.1002/cam4.71268
Vancouver
Kostun J, Nowosielski K, Jedryka MA, Hardisson D, Restaino S, Gatius S, et al. One‐Step Nucleic Acid Amplification Analysis of Sentinel Lymphatic Nodes in Endometrial Cancer Patients ( EU ‐ OSNA ): A European Multicenter Diagnostic Accuracy Study. Cancer Medicine. 2025. doi:10.1002/cam4.71268
BibTeX
@article{Kostun2025,
author = {Kostun, Jan and Nowosielski, Krzysztof and Jedryka, Marcin A and Hardisson, David and Restaino, Stefano and Gatius, Sonia and Novak, Zoltan and Lacalle, Amaia Sagasta and Lopez, Susana and Pešta, Martin and Zebalski, Marcin and Lepka, Piotr and Diestro, María Dolores and Vizzielli, Giuseppe and Matias-Guiu, Xavier and Echim, Tímea and Urkaray, Emma Natalia Camacho and Rienda, Iván and Slunečko, Robert and Czekanski, Andrzej and Berjón, Alberto and Mariuzzi, Laura and Velasco, Ana and Betenbuk, Judit and Merino, Isabel Guerra and Padilla-Iserte, Pablo and Stráník, Petr and Smoligová, Vendula and Presl, Jiří},
title = {One‐Step Nucleic Acid Amplification Analysis of Sentinel Lymphatic Nodes in Endometrial Cancer Patients ( EU ‐ OSNA ): A European Multicenter Diagnostic Accuracy Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71268}
}
EUVIMED